I-Mab Biopharma Co., Ltd. (IMAB) - שווי פעילות לרווח לפני ריבית, מסים ופחת

The price trajectory shown below for I-Mab (IMAB), which has an EV/EBITDA value of , correlates with the recruitment of global experts through generous bonuses and Western management. Following the separation from its Chinese unit, I-Mab is independently developing US research and eschewing mergers. Business resilience relies on the efficacy of oncology drugs, support from venture capital funds, and approvals from US and PRC regulators.

Analyzing I-Mab through the historical EV/EBITDA trajectory allows for a comparison of the total enterprise value, including liabilities, against its operational profitability. The current value of reflects the efficiency of generating cash flows before taxes, depreciation, and amortization. This multiple is sensitive to debt load, which is critical when financing antibody development. For a biotech company, this serves as an indicator of the ability to monetize licensing agreements with pharma behemoths.